Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

NCT05486572 · View on ClinicalTrials.gov ↗

Study Summary

The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mortality.

Interventions

  • OTHER Abbreviated Magnetic Resonance Imaging with serum AFP
  • OTHER Abdominal Ultrasound Screening with serum AFP

Study Locations (17)

California

  • VA Long Beach Healthcare System, Long Beach, CA — Long Beach
  • VA Palo Alto Health Care System, Palo Alto, CA — Palo Alto
  • VA Northern California Health Care System, Mather, CA — Sacramento
  • VA San Diego Healthcare System, San Diego, CA — San Diego
  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles

Colorado

  • Rocky Mountain Regional VA Medical Center, Aurora, CO — Aurora

Connecticut

  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven

Florida

  • James A. Haley Veterans' Hospital, Tampa, FL — Tampa

Massachusetts

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston

Michigan

  • VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor

Nebraska

  • Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha

New York

  • James J. Peters VA Medical Center, Bronx, NY — The Bronx

Trial Details

FieldValue
Enrollment Target 4,700 participants
Start Date 2023-11-03
Est. Completion 2031-09-01
Phase NA

Sponsor

VA Office of Research and Development

1,863 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05486572

The ClinicalTrials.gov registry entry for NCT05486572 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,863 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions — of which Abbreviated Magnetic Resonance Imaging with serum AFP is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05486572 reports 17 study locations spanning 13 distinct geographic areas — top geographies include California, Colorado, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05486572 about?

NCT05486572 is a clinical study titled "Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI". The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in p...

What is the current status of trial NCT05486572?

This trial is currently recruiting. It is a NA study. The enrollment target is 4,700 participants. The study started on 2023-11-03. Estimated completion is 2031-09-01.

What conditions does trial NCT05486572 study?

This clinical trial studies the following conditions: Cirrhosis, Carcinoma, Hepatocellular. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05486572?

The interventions under investigation include: Abbreviated Magnetic Resonance Imaging with serum AFP (OTHER), Abdominal Ultrasound Screening with serum AFP (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05486572?

This trial is sponsored by VA Office of Research and Development, which has 1,863 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05486572 being conducted?

This trial has 17 study locations across California, Colorado, Connecticut, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial